Introduction
Malignant tumour progression is accompanied by extensive tissue remodelling to provide a favourable environment for tumour angiogenesis, as well as for growth, invasion and metastasis of cancer cells. Metalloproteinases (that is soluble and integral membrane matrix metalloproteinases, adamalysin-related disintegrin and metalloproteinases) and serine proteases (that is the plasminogen/plasminogen activator system) have been studied extensively in these decisive tumour processes. Likewise, lysosomal cysteine proteases (Clan CA; C1 papain family), the cysteine cathepsins, have recently attracted attention as tumour-promoting enzymes (Mohamed and Sloane, 2006; Gocheva and Joyce, 2007) . Eleven human cysteine cathepsin genes are present in the human genome: cathepsins B, C (dipeptidyl peptidase I), F, H, K, L, O, S, V (L2), W (lymphopain) and X (Z) (Rossi et al., 2004) . Despite their general lysosomal localization, active cathepsins have been found extracellularly and in cellular compartments other than endosomes and lysosomes and are involved functionally in a variety of physiological and pathological processes (Turk et al., 2000; Vasiljeva et al., 2007) . There is increasing evidence that cysteine proteases, mostly cathepsins B and L and, to a lesser extent, cathepsins X, H, S and K, contribute to the proteolytic events during tumour progression (Jedeszko and Sloane, 2004) .
Cathepsin B (Ctsb) is the most abundant and widely distributed of the cysteine cathepsins and, based on immunohistological studies of human cancer samples, has been most often implicated in tumour progression (Podgorski and Sloane, 2003) . In addition to the normal vesicular localization of Ctsb, various cancer cell lines show secretion of Ctsb zymogen (Sloane et al., 1986) and plasma membrane association of activated Ctsb (Rozhin et al., 1994; Frosch et al., 1999; Vasiljeva et al., 2006) . It is now widely accepted that the tumour stroma plays an active role in cancer progression (Mueller and Fusenig, 2004; de Visser and Coussens, 2006) . Cysteine cathepsins are known to be expressed in a variety of cells of the tumour microenvironment, such as fibroblasts, macrophages, neutrophils, mast and endothelial cells (Mohamed and Sloane, 2006) . These cell types are reckoned to contribute to the tumour-promoting effects of the stroma. In particular, macrophages strongly upregulate Ctsb expression on recruitment to a tumour (McKerrow et al., 2000; Fernandez et al., 2001; Vasiljeva et al., 2006) .
Restricted expression of the polyoma middle-Toncoprotein in mammary ductal epithelium of mice results in invasive ductal mammary carcinomas that metastasize to the lungs. For this Tg(MMTV-PyMT) mouse model of breast cancer, further abbreviated as PyMT, we previously reported a significant contribution of Ctsb to macroscopic cancer progression and tumour cell invasion (Vasiljeva et al., 2006) . However, the role of Ctsb in other specific tumour processes remained unsolved. To address this in detail we compared the histopathological progression from normal to the highly malignant tissue architecture of mammary glands of PyMT;Ctsb þ / þ , PyMT;Ctsb þ /À and PyMT;Ctsb À/À mice, and investigated the role of Ctsb in cancer cell proliferation and death in this model.
Results
In order to assess the effect of Ctsb deficiency on mammary cancer development, we bred Ctsb À/À mice with transgenic mice that express the polyoma virus middle T-oncogene (PyMT) in mammary epithelial cells under control of the mouse mammary tumour virus (MMTV) long-terminal repeat (LTR) promotor. Subsequently, mice of the genotypes PyMT;Ctsb þ / þ , PyMT;Ctsb þ /À and PyMT;Ctsb À/À were compared for tumour development, cancer cell differentiation, cell proliferation and cell death.
Gross phenotype of mammary cancer
Representative images of excised left thoracic tumours of 14-week-old mice from the three cohorts show a reduced tumour burden in the PyMT;Ctsb À/À mice (Figure 1a ). At this time point the average weight of the excised total tumour mass in PyMT;Ctsb þ /À and PyMT;Ctsb À/À mice were 30% (Po0.05) and 40% (Po0.01) less than that in control mice, respectively ( Figure 1b ).
Histopathological grading of mammary cancer
Distinct stages of tumour progression from premalignant to malignant lesions occur successively in each individual mammary gland of PyMT mice (Lin et al., 2003) . In order to investigate the impact of Ctsb expression level on tumour grade, the PyMT cancers and their precursor lesions were classified in a blinded fashion into defined histopathological stages (Supplementary Figure 1 ). The histopathological progression of primary lesions to high-grade carcinomas was delayed in Ctsb-deficient mice (Figure 2 ): At 6 weeks of age 50% of PyMT;Ctsb þ / þ and 45% of PyMT;Ctsb þ /À mice had developed invasive ductal carcinomas (IDCs), whereas only 10% of PyMT;Ctsb À/À mice had progressed to this stage. At week 10, only 60% of Ctsb-deficient mice showed IDCs, in contrast to 90 and 100% of the PyMT;Ctsb þ / þ and PyMT;Ctsb þ /À groups, respectively. Although at 14 weeks of age all tumours from three cohorts of mice had developed IDCs, a significant reduction in cancer anaplasia was observed in PyMT;Ctsb À/À mice: 55% of these mice showed welldifferentiated (GI) carcinomas, while only 9 and 18% of tumours from PyMT;Ctsb þ / þ and PyMT;Ctsb þ /À mice were characterized by this grade. Accordingly, the frequency of cancers with moderately (GII) and poor (GIII) differentiation pattern was reduced in Ctsbdeficient mice.
Tumour cell proliferation
Given the substantial differences in weight and differentiation grade of PyMT-induced cancers from PyMT;Ctsb À/À and PyMT;Ctsb þ / þ mice, cell proliferation in mammary cancers and their metastasis was quantified by immunohistochemical detection of the proliferation marker Ki67 (Figures 3 and 4) . In cancers of 10-week-old PyMT;Ctsb À/À mice, the Ki67 proliferation index was reduced by about 8% (Po0.05) and 12% (Po0.05) as compared to PyMT;Ctsb þ /À and PyMT;Ctsb þ / þ mice, respectively. However, no significant difference in Ki67-positive cells between the Ctsb genotypes was detected at 14 weeks of age (Figure 3b) .
Development of lung metastasis is a hallmark of female mice expressing the MMTV-PyMT transgene (Guy et al., 1992) . At 10 weeks, PyMT;Ctsb À/À mice showed a 50% diminished metastatic burden as compared to the controls, although statistical significance was not achieved due to large inter-individual differences in this early stage of development of lung metastasis ( Figure 4a ). Importantly, at 14 weeks of age a reduced metastatic burden in lungs was detected in PyMT;Ctsb þ /À (Po0.01) and PyMT;Ctsb À/À (Po0.05) mice, with the lowest average value being that for PyMT;Ctsb þ /À mice ( Figure 4a ). Notably, compared with the PyMT;Ctsb þ / þ group, the proliferation rate of lung metastases of 14-week-old mice was significantly reduced by 40% in the PyMT;Ctsb þ /À group (Po0.001) and by 20% in the PyMT;Ctsb À/À group (Po0.05) (Figures 4b and c) . However, these differences in cell proliferation could also be attributed to the general delay of cancer and metastasis development in the two groups of mice. Therefore lung colonization experiments were performed by intravenous injection of primary
and PyMT;Ctsb
tumour cells, which show identical proliferation rates in cell culture (Vasiljeva et al., 2006) , into congenic nonPyMT-transgenic wild-type, heterozygous and Ctsbdeficient recipient mice. Ctsb deficiency in the injected tumour cell and in the recipient both resulted in reduced size of lung colonies (Vasiljeva et al., 2006) . Surprisingly, detection of Ki67 in the experimental metastases revealed significantly reduced tumour cell proliferation within lung colonies in which either the injected PyMT cells or the recipient mice were depleted, even in just one Ctsb allele (Table 1) . Moreover, injecting of tumour cells with either partial or complete deletion of Ctsb into Ctsb
-recipient mice resulted in the lowest proliferation index of only 26-27% (Po0.01) ( Table 1 ). This indicates a specific role for Ctsb in regulating cell proliferation at the tumour/host interface, in addition to its established contribution to tumour invasion.
Tumour cell death
In addition to reduced cancer cell proliferation, Ctsb genotype-dependent variations in cell death may contribute to the smaller cancers and reduced metastatic burden of PyMT;Ctsb þ /À and PyMT;Ctsb À/À mice. For this reason we performed terminal dUTP nick-end labelling (TUNEL) staining as a measure of DNA fragmentation caused by cell death in PyMT-induced mammary cancers and in the lung metastases of PyMT;Ctsb þ / þ , PyMT;Ctsb þ /À and PyMT;Ctsb À/À mice. There were no differences in the number of TUNELpositive cells in cancers and metastases between all three cohorts of mice, suggesting that Ctsb exerts no effect on PyMT tumour cell apoptosis in vivo (Figures 5a and b) . However, tumour necrosis factor-a (TNF-a)-induced apoptosis of Ctsb À/À hepatocytes was reported to be significantly reduced in vivo and in cell cultures relative to that in wild-type cells (Guicciardi et al., 2000) . We therefore exposed PyMT;Ctsb þ / þ and PyMT;Ctsb À/À primary tumour cells to TNF-a. In both Ctsb genotypes a more than twofold increase in phosphatidylserinepositive apoptotic cells was observed, however, the number of apoptotic cells in PyMT;Ctsb þ / þ and PyMT;Ctsb À/À tumour cells was the same (Figure 5c ). TNF-a-induced apoptosis was associated with conversion of the Bcl2 family member Bid to its proapoptotic form tBid; a process that was independent of the Ctsb genotype in our experimental setting (Figure 5d ). In contrast, lysosomal destabilization by the lysosomotropic agent Leu-Leu-OMe resulted in significantly reduced apoptosis of Ctsb-deficient PyMT cells ( Figure 5e) ; an effect associated with reduced Bid activation in the PyMT;Ctsb À/À cells (Figure 5f ). Taken together, these results indicate that deletion of Ctsb does not alter the susceptibility of PyMT cancer cells to the physiological apoptotic stimulus TNF-a, although Ctsb has an p=0.03 Figure 2 Histopathology of mammary glands. hematoxylin and eosin (H&E)-stained tissue sections were examined for defined histopathological stages Supplementary Figure 1 ): Normal gland (N), proliferative lesions without atypia, i.e. adenosis or moderate epithelial hyperplasia (PL), atypical ductal hyperplasia (ADH), ductal carcinoma in situ (DCIS) and invasive ductal carcinoma (IDC). The last stage was characterized by a three-grade system with respect to mitotic activity and cellular differentiation: grade I (GI), well differentiated carcinoma; grade II (GII), moderately differentiated carcinoma; grade III (GIII), poorly differentiated carcinoma. w 2 -test was used for statistical analysis (n ¼ 10-11).
Cathepsin B promotes breast cancer progression O Vasiljeva et al intrinsic ability to cleave Bid and to induce apoptosis under conditions that cause early lysosomal permeabilization.
Discussion
In this study we demonstrate the tumour-promoting role of Ctsb in a transgenic mouse model of mammary cancer. Ctsb deficiency is shown to result in reduced mammary tumour volume and in delayed progression of carcinomas to the most advanced invasive stage. It is well known that tumour progression is the result of disruption of the normal balance between cell proliferation and cell death. The processes by which this balance is disrupted determine the characteristics and evolution of the tumour (Sanchez-Beato et al., 2003) . Cell death was unaffected in mammary cancers of PyMT;Ctsb þ /À and PyMT;Ctsb À/À mice, but PyMT;Ctsb À/À mammary tissue exhibited a reduced cell proliferation rate at 10 weeks of age. However, the high percentage of ductal carcinoma in situ and well differentiated (GI) tumours and no poorly differentiated (GIII) cancers detected in PyMT;Ctsb À/À mice at 10 weeks indicated a delayed histopathological progression of the tumours. Presence of mitotic nuclei is, together with cell pleomorphism and presence of tubular structures, a main parameter for grading mammary lesions (Elston and Ellis, 1991) . Thus the reduced proliferation in tumours from 10-week-old PyMT;Ctsb À/À mice could reflect this better differentiation pattern rather than a genuine effect of Ctsb deficiency on proliferation in breast cancer tissue. However, at 14 weeks there was still a significant (Gocheva et al., 2006) . Despite the increasing number of reports implicating cysteine cathepsins in cell death processes, there is still no clear understanding of the mechanism involved (Jaattela, 2004; Stoka et al., 2005; Turk and Stoka, 2007) . Therefore, in order to investigate the possible effect of Ctsb in induced apoptosis we exposed isolated mouse primary PyMT tumour cells to TNF-a, which has been shown to markedly diminish apoptosis of hepatocytes isolated from Ctsb À/À mice (Guicciardi et al., 2000) and of transformed fibroblasts from the same mouse model (Fehrenbacher et al., 2004) . However, in our study no difference in cell death between Ctsb wild-type and knockout PyMT tumour cells was detected, suggesting that the role of Ctsb in TNF-ainduced apoptosis is cell type-specific. On the other hand, since release of lysosomal cysteine proteases into the cytosol has been proposed to be a primary requirement for their apoptotic role, we simulated early lysosomal destabilization by treating tumour cells with the lysosomotropic agent Leu-Leu-OMe. In this model of apoptosis induction, PyMT;Ctsb À/À tumour cells were found to be significantly more resistant to Leu-LeuOMe than the control PyMT tumour cells. This could be þ / þ cells treated identically. This observation is consistent with the previous studies in which lysosomal cysteine proteases were proposed to play a role in triggering the mitochondrial pathway to cell death via cleavage of Bid, a proapoptotic Bcl-2 family member (Stoka et al., 2001; Cirman et al., 2004; Blomgran et al., 2007; Nagaraj et al., 2007) . Taken together, our results suggest that absence of Ctsb in primary PyMT tumour cells does not alter their susceptibility to an inducer of tumour cell apoptosis, that is TNF-a. In light of the contradictory findings on cysteine cathepsins in cell death processes it appears reasonable to assume that such involvement is highly context-specific depending on cell type and cell stress involved (Zheng et al., 2004; Gocheva et al., 2006; Zajc et al., 2006) . Tumour cell metastasis involves a complex cascade of steps in which tumour cells disseminate, extravasate from the vessel, invade new tissue and proliferate to produce metastatic foci. Initially, we showed that PyMT;Ctsb þ /À and PyMT,Ctsb À/À cells are characterized by reduced migratory and invasive potential (Vasiljeva et al., 2006) . However, once established in the metastatic niche the volume of metastases is determined by the ratio of cell proliferation to cell death. As discussed above, deletion of Ctsb alleles did not affect tumour cell death within metastases, however, it exerted a strong negative effect on the proliferation of metastasized tumour cells. Interestingly, a major decrease in proliferation of metastasized tumour cells was detected in PyMT;Ctsb þ /À mice, thus corroborating the data of lung metastasis volumes determined with different methods (Figure 4 ; Vasiljeva et al., 2006) . In examining the pronounced reduction of lung metastasis in PyMT;Ctsb þ /À mice as compared to PyMT;Ctsb À/À mice, we found a compensatory translocation of another cysteine protease, cathepsin X, to the surface of PyMT;Ctsb À/À cells (Vasiljeva et al., 2006) . This redistribution resulted in a higher invasion potential of PyMT;Ctsb À/À cells than that of Ctsb-heterozygous PyMT cells. Cathepsin X is unique among the cysteine cathepsins in containing an RGD peptide that mediates binding to a v b 3 integrin (Lechner et al., 2006) . Strikingly, the extracellular portion of a v b 3 integrin has been shown to promote adhesion and bone metastasis of mammary epithelial cells, while the cytoplasmic b 3 enhances the tumourigenic proliferation and growth of oncogene-transformed cancer cells (Sloan et al., 2006; Huveneers et al., 2007) . Hence, redistribution of cathepsin X is likely to explain the relatively high level of metastasis and proliferation of Ctsb-deficient PyMT cells compared to PyMT;Ctsb þ /À cells (Vasiljeva et al., 2006) (Figure 4 ; Table 1 ).
In addition to the tumourigenic and pro-metastatic functions of Ctsb in the cancer cells, Ctsb originating from cells of the tumour microenvironment has the ability to induce tumour cell proliferation, as demonstrated by the present analysis of the proliferation marker Ki67 in experimental lung colonies. These results are consistent with, and provide additional explanation for, our previous finding of reduced experimental metastatic volume of mice with deleted Ctsb, in either tumour or stromal cells (Vasiljeva et al., 2006) . These findings indicate that Ctsb expressed by cells of tumour-associated stroma and/or inflammatory cells participates in the processes leading to induction of tumour cell proliferation, despite its function of proteolysis of extracellular matrix proteins. Increased Ctsb expression by stromal cells at the invasive front of the tumour node has been reported (McKerrow et al., 2000; Fernandez et al., 2001 ). In addition, there is growing evidence supporting the regulation of tumour cell proliferation by different stromal cells (for example stromal fibroblasts, myeloid cells) through secretion of mitogenic and growth factors (van Roozendaal et al., 1996; Loffek et al., 2006) . Hence, the role of Ctsb in that process could be explained by a proteolytic activity that releases matrix-or membrane-associated cytokines/ growth factors from structural and cellular components of the stroma, thereby promoting tumour growth. Thus, the present study provides evidence for the involvement of Ctsb in paracrine regulation of mammary tumour cell proliferation.
In summary, our findings indicate that depletion of Ctsb results in delayed malignant transition of mammary tumours and reduced tumour growth. Ctsb from tumour cells, as well as from the tumour microenvironment, was shown to be actively involved in promoting the proliferation of PyMT tumour cells. These results further support the concept of cysteine cathepsins as promising molecular targets for cancer therapy.
Materials and methods

Animals and tissues
The crossing of the transgenic mouse strain expressing the PyMT oncogene under the control of MMTV LTR promoter (FVB/N-TgN(MMTVPyVT)634Mul/J) (Guy et al., 1992) , here abbreviated as PyMT mice, with wild-type and Ctsb À/À mice backcrossed for seven generations have been previously reported (Vasiljeva et al., 2006) . The maintenance and breeding of the animals used in this study were performed in accordance with the German law for animal protection (Tierschutzgesetz) as published on the 25 May 1998.
Histopathology, immunohistochemistry and terminal dUTP nick-end labelling For histopathological assessment, paraffin tissue blocks of left thoracic mammary glands were sectioned and two distant tissue sections for each tumour were stained with hematoxylin and eosin (H&E) according to standard procedures. Tumours of PyMT;Ctsb þ / þ ; PyMT;Ctsb þ /À and PyMT;Ctsb À/À mice at ages of 6, 10 and 14 weeks (10 mice per group) were graded in a blinded setting by an experienced histopathologist into defined stages (Supplementary Figure 1) . Rat anti-Ki67 antibody (Dako A/S, Hamburg, Germany; 1:10 dilution) was used for detecting the proliferation marker Ki67 in epithelial and cancer cells. DNA fragmentation of dying cells was detected by in situ labelling DNA strand breaks by the terminal dUTP nick-end labelling (TUNEL) procedure (ApopTag; Oncor). For Ki67 and TUNEL data assessment five fields per tumour were randomly selected using a Â 40 objective lens and were determined in blinded setting by three independent investigators.
Lung colonization following intravenous injection of PyMT tumour cells
Primary PyMT tumour cells were obtained as previously described (Vasiljeva et al., 2006 Quantitative real-time-PCR Total RNA isolation, reverse transcription and real-time detection of SYBR-green incorporation into PCR products followed standard procedures. Primers: PyMT (forward primer: 5 0 -CTCCAACAGATACACCCGCACATACT-3 0 and reverse primer: 5 0 -GCTGGTCTTGGTCGCTTTCTGGAT AC-3 0 ) and b-actin (forward primer: 5 0 -ACCAACTGGGAC GATATGGAGAAGA-3 0 and reverse primer: 5 0 -TACGAC CAGAGGCATACAGGGACA-3 0 ).
Apoptosis induction and cell lysis
PyMT;Ctsb þ / þ or PyMT;Ctsb À/À cells were cultured at 1 Â 10 6 cells per ml in six-well plates. Cell death was induced by 18 h treatment with TNF-a at two different concentrations (50 ng ml À1 and 100 ng ml
À1
) in the presence of cycloheximide (CHX, 0.3 mg ml À1 ). The lysosomotropic agent Leu-Leu-OMe (Sigma, Hamburg, Germany) was applied at final concentrations of 1 mM, 3 mM and 5 mM. At indicated time points cells were harvested and 14 000 g (10 min) supernatants of radioimmuno precipitation assay buffer extracts (50 mM Tris, pH 8.0, 100 mM NaCl, 0.1% (w/v) SDS, 1% (v/v) Nonidet P-40, 0.5% (w/v) deoxycholic acid, 1 mM EDTA) with the addition of protease inhibitor cocktail (Sigma) were prepared. Total protein concentration was determined using the Bradford assay (Bio-Rad, Hercules, CA, USA).
Flow cytometry
Untreated and TNF-a-or Leu-Leu-OMe-treated cells were labelled with AnnexinV-PE/7AAD (BD Pharmingen, San Diego, CA, USA). The cells were then subjected to fluorescence-activated cell sorter analysis using a FACSCalibur flow cytometer (BD Biosciences, Heidelberg, Germany) and CellQuest software.
Immunoblotting
Equal amounts (75 mg) of protein were resolved in 15% SDSpolyacrylamide gel electrophoresis gels and electro-transferred to nitrocellulose membranes. Blots were probed with Bidspecific goat immunoglobulin G antibodies (R&D Systems, Minneapolis, MN, USA) and rabbit anti-b-actin antibodies (Sigma) at 1:500 and 1:1000 dilutions, respectively.
Statistical analysis
All data sets were tested for equal variances (Fisher's F-test) and normal distribution (Shapiro-Wilk test). In case of significantly different variances and/or non-normality of distribution we used the non-parametric Mann-Whitney Utest. All other numeric data were analysed by t-test (two-sided) or analysis of variance for experiments with more than two subgroups. Post hoc range tests and pair-wise multiple comparisons were performed by t-test (two-sided). Proportions were compared by w 2 -test. P-values p0.05 were considered as statistically significant.
